Oncology

18 drugs are in development for Colorectal Cancer.

BioSniper AIPage evidence connected

Prepared research question

Which programs lead the Colorectal Cancer pipeline—and what evidence could change the picture?

Traceable citations · Unknowns marked

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
elironrasib	REVOLUTION MEDICINES, INC. (RVMD)
Revumenib	Syndax Pharmaceuticals Inc (SNDX)

Phase 2(2)

Drug	Company
ngm120	NGM BIOPHARMACEUTICALS INC (NGM)
sirexatamab	CYPHERPUNK TECHNOLOGIES INC. (CYPH)

Phase 1(8)

Drug	Company
CT-202	Context Therapeutics Inc. (CNTX)
CT-95	Context Therapeutics Inc. (CNTX)
CUE-102	Cue Biopharma, Inc. (CUE)
FT836	FATE THERAPEUTICS INC (FATE)
IDE034	IDEAYA Biosciences, Inc. (IDYA)
NKTR-255	NEKTAR THERAPEUTICS (NKTR)
STRO-004	SUTRO BIOPHARMA, INC. (STRO)
tpst-1495	Tempest Therapeutics, Inc. (TPST)

Phase 1/Phase 2(6)

Drug	Company
eli-002 2p	Elicio Therapeutics, Inc. (ELTX)
iov-5001	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
lyl273	Lyell Immunopharma, Inc. (LYEL)
neo212	NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
tc-510	TCR2 THERAPEUTICS INC. (TCRR)
vs-7375	Verastem, Inc. (VSTM)

About this indication

Oncology·MeSH: Colorectal Neoplasms (D015179)

Narrower concept of MeSH descriptor Colorectal Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

BioSniper tracks 18 drugs in development for Colorectal Cancer across 17 companies.

There are 182 clinical trials targeting Colorectal Cancer tracked by BioSniper.

The estimated prevalence of Colorectal Cancer is approximately 135.0 per 100,000 population.